Stage (next event)
Catalyst Info & Data Links
TITLE: Nitazoxanide for NASH-induced significant or severe fibrosis
NCT03656068: An Evaluation of the Safety and Efficacy of NTZ on Collagen Turnover in NASH Patients With Fibrosis
WHAT IS THE NEXT CATALYST EVENT?
Phase 2 Readout
WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?
10-2020: Phase 2 Targeted Completion Date
12-15-2018: Phase 2 Enrollment
Mechanism of Action
MECHANISM OF ACTION
Our research program designed to discover novel anti-fibrotic molecules uses a phenotypic screening approach5 combined with the use of a compound library composed of FDA-approved drugs. In our model, we evaluated the compounds for their capacity to interfere with the activation of quiescent hepatic stellate cells into myofibroblasts, which are the major fibrogenic cell type in the liver.
After screening the pharmacopea, and investigating the drug candidate profiles in medical literature, we identified nitazoxanide, or NTZ; currently commercialized and prescribed in the United States and several other countries as an anti-parasitic; as a potent anti-fibrotic agent that we believe can be repurposed for the treatment of fibrosis.
Updated by MV
Prior Data (click to view full image)
Trial Design / Revenue (click to view full image)
See what the community is saying - click to see full post